Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

NCT04085250 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

264

Enrollment

OTHER

Sponsor class

Conditions

Stage III Non-small-cell Lung Cancer

Interventions

OTHER: Neoadjuvant therapy
OTHER: Chemotherapy concurrent with radiotherapy
RADIATION: Radiotherapy
DRUG: Nivolumab
OTHER: Observation

Sponsor

Sun Yat-sen University